Der er et stort gennembrud i udvikling af lægemidler til hjernetumorer i barndommen. Børns hjernetumorer er en mere almindelig malign sygdom hos børn. Nyere forskning har fundet ud af, at et nyt cocktaillægemiddel kan behandle almindelige hjernetumorer i barndommen.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain tumorer each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common ondartede tumorer of the cerebellum. This hjerne svulst grows rapidly and most often occurs in children around the age of 5. Behandlingsmuligheder include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastom survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastom. In laboratory tests, the drug killed kræft cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Ved at kombinere med andre lægemidler screenes nye forbindelser, der inhiberer tumorer in vitro og in vivo.
Kliniske forsøg for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Hvis vi kan udvikle skræddersyede behandlinger baseret på tumorgener - en strategi, der ofte betegnes som individualiseret behandling, kan dette medføre et kæmpe evangelium for patienter med visse tumorer."
Der er fire forskellige typer neuroblastom, og patienter med en tredje gruppe af tumorer har den værste prognose - kun 40% af patienterne overlever på lang sigt. I modsætning hertil er den langsigtede overlevelse af andre neuroblastomer relativt optimistisk, og ca. 80% af patienterne kan overleve på lang sigt.
De fleste af den tredje gruppe patienter med neuroblastom har høj ekspression af MYC-onkogenet, hvilket er årsagen til ukontrollabel celledeling og dannelse af tumorer.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Medical Center i Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other kræftformer, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block Cancer Cell overlevelse.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
